194 related articles for article (PubMed ID: 36603130)
21. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
[TBL] [Abstract][Full Text] [Related]
23. Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.
Koch J; Schober SJ; Hindupur SV; Schöning C; Klein FG; Mantwill K; Ehrenfeld M; Schillinger U; Hohnecker T; Qi P; Steiger K; Aichler M; Gschwend JE; Nawroth R; Holm PS
Nat Commun; 2022 Aug; 13(1):4689. PubMed ID: 35948546
[TBL] [Abstract][Full Text] [Related]
24. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix.
Topacio BR; Zatulovskiy E; Cristea S; Xie S; Tambo CS; Rubin SM; Sage J; Kõivomägi M; Skotheim JM
Mol Cell; 2019 May; 74(4):758-770.e4. PubMed ID: 30982746
[TBL] [Abstract][Full Text] [Related]
25. Altered expression of G1 regulatory proteins in human soft tissue sarcomas.
Yoo J; Park SY; Kang SJ; Shim SI; Kim BK
Arch Pathol Lab Med; 2002 May; 126(5):567-73. PubMed ID: 11958662
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
27. Aberrant expression of the Rb pathway proteins in soft tissue sarcomas.
Sabah M; Cummins R; Leader M; Kay E
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):397-403. PubMed ID: 17122635
[TBL] [Abstract][Full Text] [Related]
28. CDK4/6 Inhibition With Lerociclib is a Potential Therapeutic Strategy for the Treatment of Pediatric Sarcomas.
Julson JR; Horton SC; Quinn CH; Beierle AM; Bownes LV; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2024 Mar; 59(3):473-482. PubMed ID: 37919169
[TBL] [Abstract][Full Text] [Related]
29. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
30. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Long F; He Y; Fu H; Li Y; Bao X; Wang Q; Wang Y; Xie C; Lou L
Cancer Sci; 2019 Apr; 110(4):1420-1430. PubMed ID: 30724426
[TBL] [Abstract][Full Text] [Related]
31. MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
de Leeuw R; McNair C; Schiewer MJ; Neupane NP; Brand LJ; Augello MA; Li Z; Cheng LC; Yoshida A; Courtney SM; Hazard ES; Hardiman G; Hussain MH; Diehl JA; Drake JM; Kelly WK; Knudsen KE
Clin Cancer Res; 2018 Sep; 24(17):4201-4214. PubMed ID: 29739788
[No Abstract] [Full Text] [Related]
32. Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.
Tomosugi M; Sowa Y; Yasuda S; Tanaka R; te Riele H; Ikawa H; Koyama M; Sakai T
Cancer Sci; 2012 Dec; 103(12):2139-43. PubMed ID: 22957647
[TBL] [Abstract][Full Text] [Related]
33. Targeting cell cycle and hormone receptor pathways in cancer.
Comstock CE; Augello MA; Goodwin JF; de Leeuw R; Schiewer MJ; Ostrander WF; Burkhart RA; McClendon AK; McCue PA; Trabulsi EJ; Lallas CD; Gomella LG; Centenera MM; Brody JR; Butler LM; Tilley WD; Knudsen KE
Oncogene; 2013 Nov; 32(48):5481-91. PubMed ID: 23708653
[TBL] [Abstract][Full Text] [Related]
34. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models.
Kumarasamy V; Nambiar R; Wang J; Rosenheck H; Witkiewicz AK; Knudsen ES
Oncogene; 2022 Jul; 41(27):3524-3538. PubMed ID: 35676324
[TBL] [Abstract][Full Text] [Related]
35. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
36. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis.
Dou QP; An B; Will PL
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9019-23. PubMed ID: 7568064
[TBL] [Abstract][Full Text] [Related]
37. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.
Vijayaraghavan S; Karakas C; Doostan I; Chen X; Bui T; Yi M; Raghavendra AS; Zhao Y; Bashour SI; Ibrahim NK; Karuturi M; Wang J; Winkler JD; Amaravadi RK; Hunt KK; Tripathy D; Keyomarsi K
Nat Commun; 2017 Jun; 8():15916. PubMed ID: 28653662
[TBL] [Abstract][Full Text] [Related]
38. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer.
Chou A; Froio D; Nagrial AM; Parkin A; Murphy KJ; Chin VT; Wohl D; Steinmann A; Stark R; Drury A; Walters SN; Vennin C; Burgess A; Pinese M; Chantrill LA; Cowley MJ; Molloy TJ; ; Waddell N; Johns A; Grimmond SM; Chang DK; Biankin AV; Sansom OJ; Morton JP; Grey ST; Cox TR; Turchini J; Samra J; Clarke SJ; Timpson P; Gill AJ; Pajic M
Gut; 2018 Dec; 67(12):2142-2155. PubMed ID: 29080858
[TBL] [Abstract][Full Text] [Related]
39. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors.
Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
[TBL] [Abstract][Full Text] [Related]
40. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY; Seligson ND; Hays JL; Miles WO; Chen JL
JCO Precis Oncol; 2022 Feb; 6():e2100211. PubMed ID: 35108033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
